|

Dostarlimab Clinical Trials

22 actively recruiting trials across 7 locations

Also known as: GSK4057190A, Jemperli, TSR-042

Pipeline

Phase 1: 2Phase 2: 13Phase 3: 3Phase 1/2: 3

Top Sponsors

  • GlaxoSmithKline7
  • M.D. Anderson Cancer Center2
  • Yonsei University1
  • University of Iowa1
  • Universitaire Ziekenhuizen KU Leuven1

Indications

  • Cancer22
  • Neoplasms, Colon2
  • Gastric Adenocarcinoma2
  • Endometrial Cancer2
  • Lung Cancer2

Other14 trials

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Phase 2
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Phase 1/2
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Phase 2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Phase 2
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Phase 2
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Phase 2
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Phase 2
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Phase 1/2
PREventing Second Cancers With DOSTARlimab
Phase 2
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Phase 3
Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer
Phase 2
Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Phase 1/2
Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study
Phase 2

Houston, Texas2 trials

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

M D Anderson Cancer Center

Phase 1
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

M D Anderson Cancer Center

Phase 2

Tucson, Arizona1 trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GSK Investigational Site

Phase 3

Jonesboro, Arkansas1 trial

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

GSK Investigational Site

Phase 3

San Francisco, California1 trial

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Tampa, Florida1 trial

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Moffitt Cancer Center

Phase 2

Iowa City, Iowa1 trial

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

University of Iowa Hospitals & Clinics

Phase 2

Basking Ridge, New Jersey1 trial

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Memorial Sloan Kettering Basking Ridge (All Protocol Activites)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.